Valsts: Malta
Valoda: angļu
Klimata pārmaiņas: Medicines Authority
diclofenac sodium 100 mg
Novartis Pharmaceuticals UK Limited
M01AB05
diclofenac sodium
modified-release tablet
Authorised
2005-10-25
VOLTAREN® SR 75 AND VOLTAREN® RETARD 100MG (DICLOFENAC SODIUM) PATIENT INFORMATION LEAFLET WHAT YOU NEED TO KNOW ABOUT VOLTAREN TABLETS. Your doctor has decided that you need this medicine to treat your condition. PLEASE READ THIS LEAFLET CAREFULLY BEFORE YOU START TO TAKE YOUR MEDICINE. IT CONTAINS IMPORTANT INFORMATION. Keep this leaflet in a safe place because you may need to read it again. If you have any other questions, or if there is something you don’t understand, please ask your doctor or pharmacist. This medicine has been prescribed only for you. Never give it to somebody else. It may not be the right medicines for them even if their symptoms seem to be the same as yours. If any of the side effects affects you severely, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET 1 What Voltaren Tablets are, and what they are used for 2 Things to consider before you take Voltaren Tablets 3 How to take Voltaren Tablets 4 Possible side effects 5 How to store Voltaren Tablets 6 Further information 1 WHAT VOLTAREN TABLETS ARE, AND WHAT THEY ARE USED FOR Diclofenac sodium, the active ingredient in Voltaren tablets, is one of a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs reduce pain and inflammation, by blocking the synthesis of the molecules (prostoglandins) responsible for inflammation, pain and fever. It has no effect on the causes of inflammation or fever.Voltaren SR Tablets and Voltaren Retard Tablets are specially formulated to release the diclofenac sodium slowly. • Voltar Izlasiet visu dokumentu
Page 1 of 15 SUMMARY OF PRODUCT CHARACTERISTICS 1 TRADE NAME OF THE MEDICINAL PRODUCT VOLTAREN ® SR 75 VOLTAREN ® Retard 100 2 QUALITATIVE AND QUANTITATIVE COMPOSITION The active substance is sodium-[o[(2,6-dichlorophenyl)-amino]-phenyl]-acetate (= diclofenac sodium). One modified-release tablet contains 75 mg or 100 mg of diclofenac sodium. EXCIPIENTS Silica aerogel, cetyl alcohol, povidone, magnesium stearate, sucrose, hydroxypropyl methylcellulose, polysorbate 80, talc, titanium dioxide, red iron oxide (E 172), macrogol 8000 purified water, ethanol with 5% isopropyl, printing ink black, isopropyl alcohol, butyl alcohol. 3 PHARMACEUTICAL FORM Modified-release tablets with prolonged release of the active substance. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of: Inflammatory and degenerative forms of rheumatism: rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism. Symptomatic, short-term treatment of post-traumatic and post-operative pain (POP), inflammation, and swelling, e.g. following dental or orthopaedic surgery. Painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis . 4.2. POSOLOGY AND METHOD OF ADMINISTRATION As a general recommendation, the dose should be individually adjusted and the lowest effective dose given for the shortest possible duration. The tablets should be swallowed whole with liquid, preferably with meals and must not be divided or chewed. Page 2 of 15 Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see se Izlasiet visu dokumentu